Cachexia Combination Therapy for Immune Disorder Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cachexia, a complex metabolic syndrome associated with underlying illnesses, is currently untreated and contributes to increased morbidity and mortality, particularly in cancer patients, with no single approved treatment available.
Innovation Solution
Administering a combination of (R)-ketorolac, a non-selective COX inhibitor, and an immunosuppressive agent like cytarabine to subjects in need, at specific molar ratios and administration schedules, to effectively decrease white blood cell count, particularly neutrophils, and increase T-cell count, thereby addressing the underlying immune disorder causing cachexia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is administered for cachexia, then the patient avoids unnecessary drug exposure, but morbidity and mortality increase significantly
Solution Approach 1:
The patent changes the chemical parameter by using a specific enantiomer (R)-ketorolac instead of racemic ketorolac or other NSAIDs. This parameter change results in selective COX-1 inhibition with a favorable safety profile, enabling effective cachexia treatment without excessive gastrointestinal or cardiovascular toxicity
Solution Approach 2:
The patent combines (R)-ketorolac with immunosuppressive agents to create a composite therapeutic approach. This combination targets both the inflammatory component and the immune dysregulation in cachexia, producing synergistic effects that improve survival and reduce morbidity more effectively than either agent alone
2Reliability
If (R)-ketorolac is administered to treat cachexia, then body weight increases and survival is prolonged, but tumor growth inhibition is not achieved
Solution Approach 1:
The patent segments the treatment approach by separating the anti-cachexia effect from the anti-tumor effect. (R)-ketorolac specifically targets the cachexia pathway through selective COX-1 inhibition and immune modulation, while chemotherapy agents target tumor cells. This segmentation allows each treatment to optimize its specific function without interference
Solution Approach 2:
The patent introduces (R)-ketorolac as an intermediary agent that modifies the host's inflammatory and immune response to cachexia rather than directly attacking the tumor. This intermediary approach improves the patient's physiological state and tolerance to cancer and its treatment, indirectly supporting overall disease management
3Reliability
If combination therapy with (R)-ketorolac and immunosuppressive agent is administered, then immune disorder is corrected and body weight increases, but treatment complexity increases
Solution Approach 1:
The patent demonstrates that (R)-ketorolac performs multiple functions: it inhibits COX-1 selectively, reduces inflammation, modulates immune response, and reverses cachexia. This multi-functionality means a single agent addresses multiple pathological mechanisms, simplifying the overall treatment strategy despite the combination approach
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3B
AI summary
Provided are methods and compositions for treating cachexia in order to reduce the morbidity and mortality of chronic illnesses and to improve the effectiveness of treating chronic illness overall. More specifically, provided herein are methods and compositions for treating cachexia by agents that modulate the immune system and/or inflammation.